Press Release FeedGet the RSS feed
Menu

GlobeNewswire

Investeringsforeningen SDG Invest: Suspension i forbindelse med skift af udstederansvarlig

GlobeNewswire

August 27, 2026 04:39 ET  | Source: Investeringsforeningen SDG Invest

Investeringsforeningen SDG Invest - Andre oplysningsforpligtelser offentliggjort efter børsens regler

Suspension i forbindelse med skift af udstederansvarlig

I forbindelse med at Investeringsforeningen SDG Invest skifter udstederansvarligt institut med virkning fra 1. september 2026, vil handlen i foreningens noterede afdeling blive suspenderet fra og med mandag den 31. august 2026 til og med tirsdag den 1. september 2026.

ISINDK0061668654
Nasdaq IDSDKGBA
NavnSDG Invest Globale Bæredygtige Aktier akk.
Suspenderingsdato31. august 2026 til og med den 1. september 2026

Eventuelle henvendelser vedrørende denne meddelelse kan rettes til undertegnede på tlf. 29451330.

Med venlig hilsen
StockRate Forvaltning A/S
Marianne Skou Moltsen
Direktør

  1. FinanceAVEX Deadline in 3 DAYS: AEVEX Corp. (AVEX) Investors: October 20, 2026, Filing Deadline in Securities Fraud Class Action - Contact Kessler Topaz Meltzer & Check, LLPDid you buy AVEX Class A common stock between April 17, 2026 and June 4, 2026?
  2. FinanceXTIA DEADLINE NOTICE: ROSEN, A LONGSTANDING LAW FIRM, Encourages XTI Aerospace, Inc. Investors to Secure Counsel Before Important October 27 Deadline in Securities Class Action - XTIAWHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of XTI Aerospace, Inc. (NASDAQ: XTIA) between April 15, 2026 and August 17, 2026, both dates inclusive (the “Class Period”), of the important October 27, 2026 lead plaintiff deadline.
  3. ImpactLife blood donors contribute more than $30K for nonprofits"Good Giving" offers donors the opportunity to pay it forward with Donor Rewards
  4. Ascendis PharmaTransCon® CNP (Navepegritid), einmal wöchentlich, erhält eine positive Bewertung des CHMP für die Behandlung von Achondroplasie bei KindernDie endgültige Entscheidung der Europäischen Kommission wird für das vierte Quartal 2026 erwartet
  5. Ascendis PharmaTransCon® CNP (navepegritide), administré une fois par semaine, reçoit un avis favorable du CHMP dans le traitement de l’achondroplasie chez l’enfantLa décision finale de la Commission européenne est attendue au quatrième trimestre 2026
  6. TBLA DEADLINE OCTOBER 20th: Bragar Eagel & Squire, P.C. Urges Taboola.com Ltd. Investors with Large Losses to Contact the Firm Before the October 20th Lead Plaintiff DeadlineBragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Taboola.com (TBLA) To Contact Him Directly To Discuss Their Options